On Oct 25, 2018 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that investigators at Emory University will present animal model data supporting the potential of WP1066 to treat pediatric brain tumors at the upcoming Society for Neuro-Oncology Annual Scientific Meeting (Press release, Moleculin, OCT 25, 2018, View Source [SID1234530259]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"A number of independent institutions have published results supporting the potential for WP1066 to kill tumors in a range of animal models," commented Walter Klemp, Moleculin’s Chairman and CEO. "Having this corroborated yet again by data presented from Emory University just adds to the enthusiasm for testing WP1066 in humans. What makes this particularly important is that our drug showed activity against the most common form of childhood brain tumor, medulloblastoma, for which there is a desperate need for more effective treatments."

Mr. Klemp continued, "We are also proud of the fact that two different Moleculin technologies, WP1066 and WP1122 (see Moleculin press release dated October 10, 2018), are being presented at this prestigious conference on brain tumors. We believe this is a strong indicator of the breadth and significance of our development pipeline

On October 25, 2018 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines to control the expression of genes, reported that it will host a live conference call and webcast at 7:30 a.m. ET on Thursday, November 1, 2018 to report its third quarter 2018 financial results and provide a corporate update (Press release, Syros Pharmaceuticals, OCT 25, 2018, View Source [SID1234530204]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 3988733. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation

On October, 26 2018 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) reported that it will host a conference call and live webcast to report its 2018 third quarter financial results on Thursday, November 8, 2018 at 4:30 p.m. ET (Press release, Inovio, OCT 24, 2018, View Source [SID1234530154]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived version of the audio presentation will be available online at View Source This is a listen-only event but will include a live Q&A with analysts.

A replay of the conference call will be accessible two hours after the call at 877-481-4010 (domestic) or 919-882-2331 (international) using replay ID 39603.

On October 24, 2018 Nusano (previously known as Alpha Source Inc./Alpha Isotopes) reported that it has raised $41 million from investors, according to an Oct. 24 securities filing (Press release, Nusano, OCT 24, 2018, View Source [SID1234629349]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The developer of radioisotopes, also doing business as Alpha Isotopes, raised $41,464,543 during a seed round from 11 investors, according to a filing to the U.S. Securities and Exchange Commission.

Alpha Source launched as a limited liability corporation in 2007, was incorporated two years ago, according to the California Secretary of State.

It is now led by Dr. Howard Lewin, a cardiologist affiliated with Cedars-Sinai Medical Center and Ronald Reagan UCLA Medical Center.

The company has patented a new technology to create a range of radioisotopes to be used in medicine, Lewin said on his LinkedIn page.

Alpha Source can either make them at less cost than those currently being produced, he said. Or the company can create new radioisotopes once too costly to make that will expand the market and help develop radiopharmaceuticals for personalized cancer therapies.

On October 24, 2018 Agilent Technologies Inc. (NYSE: A) reported that it will release fourth-quarter fiscal 2018 financial results after the stock market closes on November 19 (Press release, Agilent, OCT 24, 2018, http://www.agilent.com/about/newsroom/presrel/2018/24oct-gp18056.html [SID1234530244]). The company will host a live webcast of its investor conference call in listen-only mode.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Monday, November 19, 2018
Time: 1:30 PM (Pacific Time)
Web access: http://www.investor.agilent.com

Listeners may log on and select "Q4 2018 Agilent Technologies Inc. Earnings Conference Call" in the "News & Events — Calendar of Events" section. The webcast will remain on the company site for 90 days.

In addition, a telephone replay of the conference call will be available at approximately November 19, 2018 at 4: 30 PM (Pacific Time) after the call and through November 26 by dialing +1 855-859-2056 (or +1 404-537-3406 from outside the United States) and entering pass code 6519506.